Related Experiment Videos
Modeling budgetary impact for decision makers
1Policy and Economics Group, St. John's Innovation Centre, Cambridge, UK.
Anti-Cancer Drugs
|December 1, 1993
Summary
The use of 5-HT3 receptor antagonists for acute chemotherapy-induced emesis is cost-effective. However, their use in delayed emesis presents a significant budget impact without clear clinical benefits, making it inappropriate.
Area of Science:
- Pharmacoeconomics
- Oncology
- Gastroenterology
Background:
- Chemotherapy-induced emesis is a significant side effect impacting patient quality of life.
- 5-HT3 receptor antagonists are a key class of antiemetic drugs.
- Understanding the cost-effectiveness of these agents is crucial for healthcare management.
Purpose of the Study:
- To evaluate the budgetary implications of using 5-HT3 receptor antagonists in managing chemotherapy-induced emesis.
- To determine the appropriateness of 5-HT3 receptor antagonist use in both acute and delayed phases of emesis.
Main Methods:
- Analysis of treatment costs associated with 5-HT3 receptor antagonists.
- Comparison of costs and clinical benefits in acute versus delayed emesis management.
Main Results:
- Treatment with 5-HT3 receptor antagonists in the acute phase of emesis shows minimal additional cost within standard care.
- Delayed emesis management with 5-HT3 receptor antagonists incurs substantial costs without proven clinical benefit.
Conclusions:
- 5-HT3 receptor antagonist use is justifiable for acute chemotherapy-induced emesis due to cost-effectiveness.
- Treatment for delayed chemotherapy-induced emesis with these agents is not currently appropriate due to high costs and lack of proven benefit.